Alanine, butyl ester | 50833-19-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Alanine, butyl ester
• 英文别名: butyl (2R)-2-aminopropanoate
• CAS: 50833-19-7
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: RJJXSCQQRYCPLW-ZCFIWIBFSA-N

物化性质

• 沸点：
  175.4±13.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Alanine, butyl ester 在 10% Nishimura catalyst <(45.9% Rh/19.9% Pt) oxide> 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、10.0 MPa 条件下， 反应 16.0h， 生成 D-氨基丙醇
  参考文献：
  名称：

  Catalytic Hydrogenation of Chiral α-Amino and α-Hydroxy Esters at Room Temperature with Nishimura Catalyst without Racemization

  摘要：

  The hydrogenation or carboxylic acid derivatives at room temperature was investigated. With a mixed Rh/Pt oxide (Nishimura catalyst), low to medium activity was observed for various alpha-amino and alpha-hydroxy esters. At 100 bar hydrogen pressure and 10% catalysts loading, high yields or tire desired amino alcohols and diols were obtained without racemization. The most suitable alpha-substituents were NH2, NHR, and 011, whereas beta-NH2 were less effective. Usually, aromatic rings were also hydrogenated, but with the free bases of amino acids as substrates, some selectivity was observed. No reaction was round for alpha-NR2, alpha-OR, and unfunctionalized esters; acids and amides, were also not reduced under these conditions. A working hypothesis for the mode or action of the catalyst is presented.

  DOI：

  10.1002/1615-4169(20011231)343:8<802::aid-adsc802>3.0.co;2-t
• 作为产物：
  描述：

  D-丙氨酸 、 正丁醇 在 氯化亚砜 作用下， 生成 Alanine, butyl ester
  参考文献：
  名称：

  合成甜味剂。3.来自L-和D-烷基甘氨酸的天冬氨酰二肽酯。

  摘要：

  DOI：

  10.1021/jm00269a014

文献信息

• [EN] DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDE ET DE TRIPEPTIDE ÉPOXY CÉTONE PROTÉASES
  申请人：ONYX THERAPEUTICS INC

  公开号：WO2014152127A1

  公开（公告）日：2014-09-25

  Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.

  本文提供了二肽和三肽环氧酮蛋白酶抑制剂，其制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了化合物的化学式（X）：及其药用盐和包括这些化合物的组合物。本文提供的化合物和组合物可以用于治疗增生性疾病，包括癌症和自身免疫疾病。
• [EN] GAMMA AMINO ACID BUILDING BLOCKS<br/>[FR] ÉLÉMENTS CONSTITUTIFS DE GAMMA-AMINOACIDES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2011047190A1

  公开（公告）日：2011-04-21

  The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a pro line derivative to provide cyclically constrained α-substituted-γ-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected γ- amino acid residues, which are essential for systematic conformational studies of γ-peptide foldamers. New methods are also provided to prepare other γ-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as α/γ-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.

  该发明提供了化合物和方法，例如，用于催化贝氏碱衍生物对环状约束硝基乙烯化合物进行醛的有机催化Michael加成，从而提供环状约束的α-取代-γ-硝基醛。当使用手性吡咯烷催化剂时，反应可以实现对映选择性，从而以几乎光学纯形式（例如，96%至>99% e.e.）获得Michael加合物。Michael加合物可以在羰基相邻处携带单取代基或双取代基。Michael加合物可以高效转化为环状约束的保护γ-氨基酸残基，这对于γ-肽折叠体系的系统构象研究至关重要。还提供了制备其他γ-氨基酸和肽的新方法。这些新的构建模块可用于制备折叠体，例如α/γ-肽折叠体，在溶液中和固态中采用特定螺旋构象。
• Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof
  申请人：Kolb Hartmuth C.

  公开号：US20120282180A1

  公开（公告）日：2012-11-08

  The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention.

  本发明涉及治疗和诊断剂的领域，更具体地涉及式（I）化合物，它们是基质金属蛋白酶（MMPs）的抑制剂，可用于治疗与之相关的疾病，如心血管疾病、炎症性疾病和恶性疾病。本发明的一种实施例是一种带有18-氟原子的式（I）化合物，具有适用于诊断成像的基质金属蛋白酶抑制活性。本发明还揭示了一种制剂，其中包括本发明的基质金属蛋白酶抑制剂或相应的标记化合物，适用于哺乳动物给药的形式。此外，本发明还揭示了合成本发明的基质金属蛋白酶抑制剂和诊断成像剂的中间体，以及制备本发明的制剂的工具箱。
• DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
  申请人：ONYX THERAPEUTICS, INC.

  公开号：US20160031934A1

  公开（公告）日：2016-02-04

  Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.

  本文提供了二肽和三肽环氧酮蛋白酶抑制剂，其制备方法，相关的药物组合物以及使用方法。例如，本文提供了化合物X的公式和包括其在内的药学上可接受的盐和组合物。本文提供的化合物和组合物可以用于治疗增殖性疾病，包括癌症和自身免疫性疾病。
• Antiviral phosphodiamide prodrugs of tenofovir
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10745428B2

  公开（公告）日：2020-08-18

  Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

  式 I 的化合物及其药学上可接受的盐类和共晶体可用于抑制 HIV 逆转录酶。这些化合物还可用于预防或治疗艾滋病病毒感染，以及预防、延缓艾滋病的发生、发展和治疗。这些化合物及其盐类可用作药物组合物的成分，也可与其他抗病毒剂、免疫调节剂、抗生素或疫苗结合使用。